Results 191 to 200 of about 555,884 (236)
Some of the next articles are maybe not open access.
Access to Databases in Complementary Medicine
The Journal of Alternative and Complementary Medicine, 2000Access to medical databases is a keystone for obtaining up-to-date and complete information for physicians. In the last few years, the rapid growth of the World Wide Web has given rise to an information revolution, enabling health care providers to gain access (often free) to an expanding volume of information that was previously inaccessible.
Allais G +4 more
openaire +2 more sources
Pathways to faster access to medicines
Drug and Therapeutics Bulletin, 2018Before a medicine can be marketed in the UK, marketing authorisation approval is needed from the European Medicines Agency (EMA) or the Medicines and Healthcare products Regulatory Agency (MHRA). However, the time it takes to appraise a medicine is considered by some to delay access to new treatments for people with serious or life-threatening ...
openaire +2 more sources
Understanding access to genitourinary medicine services
International Journal of STD & AIDS, 2004In this study we describe waiting times in genitourinary medicine clinics (England, Wales, Northern Ireland), describe patterns of clinic attendance over time, and explore the association between waiting times and attendance patterns. A postal survey of clinicians in October 2002 explored waiting times and appointment policy.
V, Griffiths +2 more
openaire +2 more sources
Access to cancer medicines in India
The Lancet Oncology, 2013An editorial in The Lancet Oncology stated “It could be argued that since access to—and resources for—cancer treatment are so limited in developing countries, the answer lies in a greater reliance on generic drugs.” We agree, but the real question is how best can such generic drug production be stimulated?
Sandeep P, Kishore +2 more
openaire +2 more sources
UK Early Access to Medicines Scheme
The Lancet Oncology, 2014The UK’s Early Access to Medicines Scheme has awarded its fi rst Promising Innovative Medicine desig nation. DCVax-L, an immuno therapy for glioblastoma developed by Northwest Biotherapeutics (Bethesda, MD, USA), was granted the status after its initial clinical trial data was assessed by the Medicines and Healthcare products Regulatory Agency (MHRA ...
openaire +2 more sources
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly